Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 52-Week, Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD) (MAESTRO-NAFLD-1)

NCT04197479 is registered in ClinicalTrials.gov with Madrigal Pharmaceuticals, Inc. as lead sponsor.

NCT NCT04197479
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04197479 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 52-Week, Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD) (MAESTRO-NAFLD-1)
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
December 16, 2019
Completion date
January 6, 2023
Enrollment
1,343 (actual)
Sites
77

Conditions

As the registry lists them; a condition with its own page is linked.

non-alcoholic fatty liver disease